Literature DB >> 26703117

Comparison of the multidetector-row computed tomography findings of IgG4-related sclerosing cholangitis and extrahepatic cholangiocarcinoma.

M Yata1, K Suzuki2, N Furuhashi2, K Kawakami2, Y Kawai3, S Naganawa2.   

Abstract

AIM: To compare the multidetector-row computed tomography (MDCT) findings of IgG4-related sclerosing cholangitis (IgG4-SC) and extrahepatic cholangiocarcinoma (EH-CCA).
MATERIALS AND METHODS: Two radiologists who had no knowledge of the patients' clinical information retrospectively evaluated the CT findings of patients with IgG4-SC (n=33) and EH-CCA (n=39) on a consensus basis. Another radiologist measured the biliary lesions. IgG4-SC was diagnosed using the Japan Biliary Association criteria (2012) or the Mayo Clinic's HISORt criteria. EH-CCA was diagnosed based on surgical findings.
RESULTS: Compared with EH-CCA, IgG4-SC exhibited the following findings significantly more frequently: (a) wall thickening alone, (b) concentric wall thickening, (c) smooth inner margins, (d) homogeneous attenuation in the arterial phase, (e) a lesion involving the intrapancreatic bile duct, (f) smooth outer margins, (g) fully visible lumen, (h) a funnel-shaped proximal bile duct, (i) skip lesions, and (j) abnormal pancreatic findings. Conversely, (k) dual-layered attenuation in all phases was significantly more common in EH-CCA. The specificity values of parameters (e-k) were >80%. Regarding dimensions, (l) the biliary lesions were longer in IgG4-SC than in EH-CCA. (m) The diameters of the dilated proximal common bile duct and (n) the dilated proximal intrahepatic bile duct were smaller in IgG4-SC than in EH-CCA.
CONCLUSION: A number of CT findings are useful for differentiating between IgG4-SC and EH-CCA. CT findings (e-k) are particularly useful for this purpose.
Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26703117     DOI: 10.1016/j.crad.2015.10.024

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations.

Authors:  J-Matthias Löhr; Ulrich Beuers; Miroslav Vujasinovic; Domenico Alvaro; Jens Brøndum Frøkjær; Frank Buttgereit; Gabriele Capurso; Emma L Culver; Enrique de-Madaria; Emanuel Della-Torre; Sönke Detlefsen; Enrique Dominguez-Muñoz; Piotr Czubkowski; Nils Ewald; Luca Frulloni; Natalya Gubergrits; Deniz Guney Duman; Thilo Hackert; Julio Iglesias-Garcia; Nikolaos Kartalis; Andrea Laghi; Frank Lammert; Fredrik Lindgren; Alexey Okhlobystin; Grzegorz Oracz; Andrea Parniczky; Raffaella Maria Pozzi Mucelli; Vinciane Rebours; Jonas Rosendahl; Nicolas Schleinitz; Alexander Schneider; Eric Fh van Bommel; Caroline Sophie Verbeke; Marie Pierre Vullierme; Heiko Witt
Journal:  United European Gastroenterol J       Date:  2020-06-18       Impact factor: 4.623

2.  Differentiating IgG4-related sclerosing cholangiopathy from cholangiocarcinoma using CT and MRI: experience from a tertiary referring center.

Authors:  Jordan Swensson; Temel Tirkes; Mark Tann; Enming Cui; Kumaresan Sandrasegaran
Journal:  Abdom Radiol (NY)       Date:  2019-06

3.  Isolated IgG4-related sclerosing cholangitis misdiagnosed as malignancy in an area with endemic cholangiocarcinoma: a case report.

Authors:  Narongsak Rungsakulkij; Pattana Sornmayura; Penampai Tannaphai
Journal:  BMC Surg       Date:  2017-02-15       Impact factor: 2.102

4.  Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant.

Authors:  Wei Liu; Qiaofei Liu; Wenqin Wang; Penghui Wang; Jieming Chen; Tao Hong; Ning Zhang; Binglu Li; Qiang Qu; Xiaodong He
Journal:  J Cancer       Date:  2018-04-19       Impact factor: 4.207

Review 5.  Immunoglobulin G4-related sclerosing cholangitis.

Authors:  George Goodchild; Stephen P Pereira; George Webster
Journal:  Korean J Intern Med       Date:  2018-07-27       Impact factor: 2.884

6.  Clinical guidelines for primary sclerosing cholangitis 2017.

Authors:  Hiroyuki Isayama; Susumu Tazuma; Norihiro Kokudo; Atsushi Tanaka; Toshio Tsuyuguchi; Takahiro Nakazawa; Kenji Notohara; Suguru Mizuno; Nobuhisa Akamatsu; Masahiro Serikawa; Itaru Naitoh; Yoshiki Hirooka; Toshifumi Wakai; Takao Itoi; Tomoki Ebata; Shinji Okaniwa; Terumi Kamisawa; Hiroki Kawashima; Atsushi Kanno; Keiichi Kubota; Masami Tabata; Michiaki Unno; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2018-06-27       Impact factor: 7.527

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.